ANP32E and breast cancer: SMYD3 suppresses the methylation of H2A.Z1, thereby inhibiting Anp32e-mediated dissociation of H2A.Z1 from chromatin, increasing cyclin A1 expression, and encouraging breast cancer progression [37].